Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
Background Colitis is one of the common immune-related adverse events that leads to morbidity and treatment discontinuation of immunotherapy. The clinical presentation, endoscopic and histopathological features and best management of this toxicity are not well defined.Patients and methods Patients w...
Saved in:
| Main Authors: | Serigne Lo, Georgina V Long, Richard A Scolyer, Matteo Carlino, Kazi J Nahar, Robert V Rawson, Tasnia Ahmed, Stephen Tattersall, Neomal Sandanayake, Christopher J Kiely, Umaimainthan Palendira, Alexander M Menzies |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001488.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
by: A. A. Formozo, et al.
Published: (2021-01-01) -
Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01) -
Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01) -
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
by: Bartosz Chmielowski
Published: (2013-01-01) -
Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)